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Abstract. Most Pharmacological chaperones (PC’s) described until now are 
substrate analogues which bind to the active site of the target protein. Conse-
quently, such PC’s also inhibit the target protein at higher concentrations thus 
rendering a narrow therapeutic window and have poor drug-like properties. 
Through our proprietary technology platform SEE-Tx™, we identify a new 
generation of non-substrate competitive pharmacological chaperones which po-
tentially offer a much broader therapeutic window. What’s more, such com-
pounds are not substrate analogues, thus presenting much better drug-like prop-
erties, particularly for indications with CNS involvement. Here we present our 
methodology to identify non-competitive pharmacological chaperones applied 
to the enzyme beta-galactosidase, whose deficiency is related with GM1 
Gangliosidosis and Morquio B.  
Keywords: Pharmacological chaperones, Chemical chaperones, Enzyme en-
hancement therapy, GM1, Gangliosidosis, Morqui B, Lysosomal Storage Disease, 
Lysosomal Storage Disorders. 
1 Introduction. 
Many monogenic diseases are characterized by the presence of missense mutations 
which affect the folding and stability of a key enzyme, which is then degraded by the 
quality control machinery of the cell. This deficiency of enzymatic activity is what 
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originates the diseases. Pharmacological chaperones are a new class of small mole-
cule drugs, which showed great potential for the treatment of such genetic diseases. 
They prevent the degradation of unstable enzymes with missense mutations, thus 
producing an enzyme enhancement effect normalizing enzymatic activity, which re-
verses and/or prevents disease progression. 
There are several examples where pharmacological chaperones showed excellent 
efficacy in preclinical models. Nonetheless, success in clinical development has been 
somehow modest. Such pharmacological chaperones usually were substrate-like com-
pounds which competed with such substrate, thus they inhibited the enzyme at higher 
concentrations and tend to presented poor drug like properties. 
Pharmacological chaperone therapy has been largely experimented on the 
lysosomal storage diseases [1,2], starting with the pioneer work on Fabry disease in 
1999[3]. 
 
2 Methodology.  
Using the three-dimensional structure of proteins and proprietary computational 
technology, we identify and exploit previously uncharacterized druggable binding 
sites. In a first step, fast methods are used to identify putatively druggable sites. This 
is done with fpocket an open source program that automatically identifies cavities and 
assigns a druggability score[4,5]. This can be supplemented with visual inspection. 
Interesting systems are then subjected to molecular dynamics simulations with aque-
ous/organic solvent mixtures (MDmix). Analysis of solvation propensities reveals the 
presence of binding hot spots, which are clustered to identify druggable binding 
sites[6]. It is worth noting that the catalytic site of enzymes involved in lysosomal 
storage diseases are often considered not druggable because they are too small and 
polar, as expected for sugar-binding sites. However, a significant portion of the pro-
teins investigated (~30%) present allosteric cavities that are predicted as druggable.  
A range of organic solvents are investigated with MDmix simulations, and the ob-
served densities for each atom type are converted to binding free energies with a pro-
prietary method, which can be used to predict the binding free energy of a putative 
ligand[7]. This information is used to supplement a molecular docking program, 
which evaluates the chemical and shape complementarity of virtual compounds. A 
unified catalogue containing millions of compounds from a list of preferred vendors 
can be filtered in this manner. The most promising virtual hits are then purchased and 
subjected to experimental assays which evaluate effect on protein stability and en-
zyme enhancement activity (Fig.1). 
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 Fig. 1. Self-explanatory graphic of the methodology used to discover non-competitive pharma-
cological chaperones. 
3 Beta-galactosidase deficit disorders (GM1 – gangliosidosis 
and Morquio B). 
Two lysosomal storage disorders, GM1 and Morquio B, are produced by the defi-
ciency of the enzyme beta-galactosidase due to mutations in the GLB1 gene. This 
enzyme cleaves beta-galactoses from different substrates which are then accumulated 
in the body. GM1 Gangliosidosis is a neurodegenerative disease that affects severely 
the CNS and other organs.  The disease is classified into three clinical types according 
to the age of onset and the symptom severity: type I (infantile form), type II (late in-
fantile/juvenile form) and type III (adult form) [8]. Morquio B disease is characterized 
by typical massive skeletal changes, cornea clouding and deficient cardiac function. 
Several compounds have been found as pharmacological chaperones for GM1 be-
ing the most advanced NOEV [9] and 6S-NBI-DGJ [10]. Interestingly, although both 
compounds bind to the active site, they show different responsive profile when tested 
on a panel of GLB1 mutations [11].  
3.1 Screening 
We applied our methodology to identify druggable binding sites different from the 
active-site. We use the published 3D structure obtained by X-ray crystallography and 
refined to 1.8 Å resolution [12]. A druggable cavity was identified initially with an 
empirical model implemented in fpocket [4,5]. The druggability of the cavity was 
then confirmed with a physics-based method consisting in molecular dynamics simu-
lations of the protein in organic-aqueous solvent mixtures [6,7]. The same method 
was used to identify key interaction sites (binding hot spots), which were used as 
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pharmacophoric restraints to guide docking. A virtual collection of several million 
commercially-available compounds were evaluated with the docking program rDock 
using the standard scoring function, pharmacophoric restraints and a high-throughput 
protocol[13]. The best scoring compounds were visually inspected and a subset of 
them (virtual hits) was selected based on the plausibility of the binding mode and 
chemical diversity considerations. Virtual hits where identified and tested on the DSF 
assay (Differential scanning fluorimetry). The DSF technique was also used as prima-
ry screening to optimize the hits. The hits identified were small molecules with excel-
lent ligand efficiency having potency in the M range (Fig.2). Those molecules were 
non-sugar like molecules with a SAR (structure–activity relationship) consistent with 
the predicted binding mode on the new binding site. 
 
 
 
 
                            A                                                                     B 
Fig. 2. A) Compounds tested on the DSF assay. m is expressed as relative to reference com-
pound DGJ.  B) Kd for compound #6. 
Several chemical series has been identified and round 80 compounds have been 
synthesized until now on the optimization process. 
3.2 Enzyme inhibition. 
Contrary to substrate-competitive PC’s, our compounds did not present inhibitory 
activity on the enzyme. To test the enzyme inhibition we compared our compounds 
with reference compounds such as DGJ and NN-DGJ on an inhibition experiment, 
both with purified hGLB1 and lysates from human fibroblasts (Fig.3). Similar results 
were obtained. 
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Fig. 3. Inhibitory activity on the enzyme with lysates from normal human fibroblast. A) Refer-
ence compound DGJ. B) Reference compound NN-DGJ. C) Non-competitive pharmacological 
chaperones #1, #2, #7. 
3.3 Enzyme enhancement in cells. 
We tested enzyme enhancement activity of our compounds on a panel of COS cells 
transfected with hGLB1, either wild type (WT) or pathologic mutants. 
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Fig. 4. Enzyme enhancement activity of compound #3 on COS cells transfected on : A) WT 
protein. B) T420K mutated protein. C) Y83C mutated protein (Morquio B). 
Results showed consistent enzyme enhancement activity in cell-based assays either 
with WT or with selected mutants at 100 M. The enzyme enhancement activities are 
on the same range as with DGJ but at 5X lower concentration (Fig.4). Enzyme en-
hancement activity by using GM1 patients and in mutant mouse fibroblasts is ongo-
ing. 
Apparently, responsiveness to mutations is also related to the binding site and the 
degree of unstabilizing effect of the specific mutation. The profile of responsive muta-
tions and the magnitude of enzyme enhancement may be rather different among non-
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competitive and substrate competitive compounds. Combination of pharmacological 
chaperones targeting different binding sites may offer an avenue for broadening their 
therapeutic window and increasing the number of responsive mutations. 
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